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Abstract
Skp1-Cul1-F-box protein (SCF) ubiquitin ligases direct cell survival
decisions by controlling protein ubiquitylation and degradation.
Sufu (Suppressor of fused) is a central regulator of Hh (Hedgehog)
signaling and acts as a tumor suppressor by maintaining the Gli
(Glioma-associated oncogene homolog) transcription factors inac-
tive. Although Sufu has a pivotal role in Hh signaling, the players
involved in controlling Sufu levels and their role in tumor growth
are unknown. Here, we show that Fbxl17 (F-box and leucine-rich
repeat protein 17) targets Sufu for proteolysis in the nucleus. The
ubiquitylation of Sufu, mediated by Fbxl17, allows the release of
Gli1 from Sufu for proper Hh signal transduction. Depletion of
Fbxl17 leads to defective Hh signaling associated with an impaired
cancer cell proliferation and medulloblastoma tumor growth.
Furthermore, we identify a mutation in Sufu, occurring in medul-
loblastoma of patients with Gorlin syndrome, which increases Sufu
turnover through Fbxl17-mediated polyubiquitylation and leads to
a sustained Hh signaling activation. In summary, our findings
reveal Fbxl17 as a novel regulator of Hh pathway and highlight
the perturbation of the Fbxl17–Sufu axis in the pathogenesis of
medulloblastoma.
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Introduction
Signals of the Hh (Hedgehog) pathway are essential in directing cell
proliferation and patterning during embryogenesis (Hooper & Scott,
2005; Ingham et al, 2011). The pathway lays at the cross-road of cell
survival and differentiation decisions, and unscheduled Hh signaling
can lead to hyperproliferation and the development of malignancies.
Indeed, alterations of pathway components have been described in
multiple cancer types (Teglund & Toftgard, 2010).
Hh signaling is initiated at the cell membrane by the inactivation
of the 12-pass transmembrane receptor Ptch (Patched) upon binding
of the Hh ligands (Ingham et al, 2011). Ptch inactivation frees the
cognate receptor Smo (Smoothened) leading to the downstream acti-
vation of a transcriptional program mediated by Gli1, Gli2, and Gli3
(Glioma-associated oncogene homolog 1, 2, and 3) transcription
factors (Hui & Angers, 2011).
Sufu (Suppressor of fused) acts as a central negative regulator of
Hh signaling by sequestering the Gli transcription factors in an inac-
tive complex (Kogerman et al, 1999; Dunaeva et al, 2003; Merchant
et al, 2004; Humke et al, 2010). Sufu deletion in mice leads to the
continuous activation of Hh signal and embryonic lethality at day
9.5 (Cooper et al, 2005; Svard et al, 2006), underscoring the essen-
tial role of Sufu for proper development. Importantly, heterozygous
loss of Sufu, in conjunction with the loss of p53, leads to the devel-
opment of medulloblastoma and rhabdomyosarcoma (Lee et al,
2007). Germline Sufu mutations have been identified in medul-
loblastoma (Taylor et al, 2002; Kool et al, 2014) and associated
with the development of medulloblastoma in Gorlin syndrome
(Pastorino et al, 2009; Kijima et al, 2012; Smith et al, 2014). Further-
more, somatic Sufu mutations have been identified in multiple
other malignancies, including prostate cancer (Sheng et al, 2004).
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Sufu has a pivotal role in Hh signaling and is a relevant tumor
suppressor, but the players involved in controlling Sufu levels are
unknown and the relevance for cancer proliferation remains
unrecognized.
Using an unbiased proteomic approach, we have identified Sufu
as an interacting partner of the E3 ubiquitin ligase Fbxl17 (F-box
and leucine-rich repeat protein 17). Fbxl17 belongs to a family of E3
ubiquitin ligases containing a leucine-rich repeat and an F-box
motif, which mediate binding to Skp1 (S-phase kinase-associated
protein 1) (Skaar et al, 2009). Skp1 in turn recruits Cul1 (Cullin 1)
and Rbx1 (RING-box protein 1) for the formation of an SCF (Skp1-
Cul1-F-box protein) complex. The multi-subunit SCF directs the
polyubiquitylation of target substrates by recruiting an E2 enzyme
with an activated ubiquitin molecule ready to be transferred on
accepting lysines of target substrates. Substrate specificity is dictated
by the presence of variable protein–protein interaction domains
within diverse F-box proteins (Skaar et al, 2013). According to the
type of protein–protein interaction domain, three subfamilies of
F-box proteins have been identified in the human genome: Fbxws
(containing WD40 repeats), Fbxls (containing leucine-rich repeats,
LRR), and Fbxos (containing other interacting motifs) (Jin et al,
2004).
F-box proteins can function as tumor suppressor or oncogenes
and have been implicated in the control of cell proliferation and
cancer development (D’Angiolella et al, 2012; Bassermann et al,
2014). Novel compounds targeting F-box proteins have been devel-
oped, and therefore, F-box proteins represent candidate pharmaco-
logical targets to treat cancer (Skaar et al, 2014). However, few
F-box proteins have been matched to substrates and biological roles.
Here, we show that Fbxl17 forms a functional SCF complex and
targets the tumor suppressor Sufu for proteolysis in the nuclear
compartment upon Hh pathway activation. The ubiquitylation of
Sufu, mediated by Fbxl17, allows the release of Gli1 for full activation
of the Hh signaling. Extending our basic biological finding to the
significance of the Fbxl17–Sufu axis in vivo, we have identified
Fbxl17 as a crucial regulator of cell proliferation in medulloblastoma.
Finally, we show that in human disease, a somatic mutation in
Sufu, occurring in medulloblastoma of patients with Gorlin
syndrome, increases Sufu turnover through Fbxl17 polyubiquityla-
tion, leading to a sustained Hh signaling and cell proliferation. Our
study highlights the alteration in Fbxl17–Sufu axis as an etiological
mechanism of medulloblastoma.
Results
Fbxl17 interacts with Sufu and regulates Sufu levels
To identify the putative functions and substrates of Fbxl17, we
isolated Fbxl17 and interacting proteins from HEK293T cells. Liquid
chromatography–tandem mass spectrometry (LC-MS/MS) of the
immunoprecipitated material identified peptides corresponding to
components of the SCF complex (Skp1 and Cul1), peptides corre-
sponding to BACH1 (BTB and CNC homology 1 protein, a known
substrate of Fbxl17) (Tan et al, 2013) as well as putative novel
substrates such as Sufu and ZBTB33 (Zinc Finger and BTB domain
containing 33) (Table 1).
Since a single substrate might be targeted by different ligases
(like in the case of b-TrCP1 and b-TrCP2; beta-transducin repeat
containing E3 ubiquitin protein ligase 1 and 2) (Guardavaccaro
et al, 2003), we screened a panel of Flag-tagged F-box proteins
isolated from HEK293T cells for the binding to Sufu. We detected
Sufu only in Fbxl17 co-immunoprecipitates (Fig 1A), whereas all
F-box proteins bound to Skp1.
Table 1. Proteins associated with Fbxl17 identified by mass spectrometry.
Accession Score Mass
No.
matches
No. sig.
matches No. seq
No. sig.
seq emPAI Description
Q9UF56 33,624 77,984 1,316 1,081 76 74 178.17 Fbxl17
P63208 8,032 18,817 297 243 17 15 59.82 Skp1
Q13616 248 90,306 14 12 9 7 0.28 Cul1
Q9UMX1 112 54,255 9 5 3 3 0.27 Sufu
Q96DT7 102 95,975 6 3 4 3 0.11 ZBTB10
Q9BY89 79 197,617 9 4 9 4 0.07 KIAA1671
Q86T24 65 75,065 1 1 1 1 0.04 ZBTB33
O14867 59 83,844 2 1 2 1 0.04 BACH1
O43318 55 67,895 4 2 4 2 0.10 TAB 1
O43164 39 79,192 3 1 3 1 0.04 Praja2
Q04721 21 279,082 5 2 3 1 0.01 Notch 2
Q9BXU1 20 116,647 7 1 3 1 0.03 SgK396
O14641 17 79,184 5 1 5 1 0.04 DSH homolog 2
O15355 16 59,919 9 2 6 2 0.11 PPM1G
The table represents the summary of four independent 3×Flag-tagged Fbxl17 immunoprecipitation experiments followed by liquid chromatography–mass
spectrometry (LC/MS). Identified interacting proteins in Fbxl17 were filtered using LC/MS data from 8 independent analyses of unrelated F-box proteins 3×Flag
immunoprecipitations. Results were scored according to confidence of identification and a Mascot Mowse cutoff score of 50 was established. Proteins identified
with a Mascot cutoff score below 50 in more than one biological replicate are also reported.
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To confirm that the binding between Fbxl17 and Sufu was not
due to spurious interaction due to Fbxl17 overexpression, we
isolated endogenous Sufu after treating cells with an inhibitor of
NAE (Nedd8-activating enzyme) (MLN4924) (Soucy et al, 2009).
This treatment blocks cullin neddylation required for the activity of
SCF ubiquitin ligases (Ohh et al, 2002). Using this approach, we
detected endogenous Fbxl17 in Sufu immunoprecipitates (Fig 1B
and C, lane 2) using an antibody against the endogenous protein. To
confirm the validity of the antibody for immunoprecipitation and
Western blot, we compared Fbxl17 detected in Sufu-immunoprecipi-
tated material to an Fbxl17, which was exogenously expressed
(Fig 1B and C, lane 3). The interaction between endogenous Fbxl17
and Sufu was validated in PC3 (human prostate cancer cell line)
and DAOY (medulloblastoma cancer cell line) (Fig 1B and C), indi-
cating that Fbxl17 and Sufu interact specifically, physiologically,
and in different cell lines.
To assess whether Fbxl17 affects Sufu levels, we measured the
protein levels of Sufu in PC3 and DAOY cells upon Fbxl17 depletion
using short interfering RNA (siRNA) (Fig 1D). Fbxl17 depletion by
two siRNAs increased Sufu protein levels in both PC3 and DAOY
(Fig 1E). Opposite to this, exogenous expression of Myc-tagged
Fbxl17 led to the downregulation of Sufu protein in both cell lines
(Fig 1F). Sufu protein levels upon either Fbxl17 depletion or overex-
pression were quantified (Fig EV1A and B). Sufu mRNA levels
remained unchanged upon the modulation of Fbxl17 levels
(Fig EV1C and D), suggesting that Sufu is regulated by Fbxl17
through a post-translational mechanism. To exclude other mecha-
nisms of control on Sufu by Fbxl17, we measured Sufu half-life in
cells where Fbxl17 was depleted using two different siRNAs. While
Sufu half-life was approximately 6 h in cells treated with a nontar-
geting siRNA, this increased to more than 12 h in Fbxl17-depleted
cells (Fig 1G). Protein levels of Sufu, upon CHX treatment, were
quantified in Fig EV1E and mRNA levels of Fbxl17 were measured
by qPCR in Fig EV1F.
SCFFbxl17 mediates Sufu polyubiquitylation
In order to assess whether Fbxl17 is directly targeting Sufu, we
measured Sufu polyubiquitylation in cells where Fbxl17 was
depleted by siRNA. Remarkably, Sufu polyubiquitylation was
completely abolished by Fbxl17 siRNA in both DAOY and 293T
cells (Fig 2A–C), supporting the role of Fbxl17 as the major
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Figure 1. Fbxl17 interacts with Sufu and regulates Sufu levels.
A Detection of Sufu and Skp1 after immunoprecipitation of the indicated Flag-tagged F-box proteins (FBPs). An empty vector (EV) was used as a negative control.
HEK293T cells were treated with MLN4924 (2 lM) for 5 h prior to collection. Representative image of three independent experiments is shown.
B, C Immunoprecipitation of endogenous Sufu from PC3 (B) and DAOY cells (C) transfected with either an empty vector (EV) or Myc-tagged Fbxl17. Nonspecific rabbit
immunoglobulin G (IgG) was used as a negative control. Detection of light chains of immunoglobulin (IgG) was used to assess the amount of IgG used for each
immunoprecipitation reaction. Treatment with MLN4925 (2 lM) was started 5 h before the cell collection.
D Quantification of Fbxl17 mRNA levels in PC3 and DAOY cells transfected with a nontargeting siRNA (Control) or two siRNAs to Fbxl17 (1) and (2). The cells were
serum-starved for 24 h in serum-reduced medium and treated with SAG (100 nM) for 24 h prior to collection. Data are shown as mean  SEM.
E Sufu protein levels in PC3 and DAOY cells treated as in (D). GAPDH was used as a loading control. Representative image of three independent experiments is shown.
F Sufu protein levels in PC3 and DAOY cells infected with an empty backbone retrovirus (EV) or a retrovirus expressing Myc-tagged Fbxl17. Representative image from
three independent experiments is shown.
G Detection of Sufu protein levels following cycloheximide (CHX) treatment for the indicated hours, and Fbxl17 depletion using two different siRNAs (Hrs = h).
Representative image of two independent experiments is shown.
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physiological ubiquitin ligase for Sufu in different cellular
systems.
Deletion mapping analysis showed that the carboxyl terminus of
Fbxl17 containing the leucine zipper motif is essential for Sufu
binding, whereas the amino terminus and the F-box motif of Fbxl17
were dispensable for Sufu recruitment (Fig EV2A and B). To con-
firm that polyubiquitylation of Sufu was due to Fbxl17 activity, we
measured Sufu polyubiquitylation using an Fbxl17 lacking the F-box
domain (that is still able to interact with Sufu, but not with Skp1;
Fig EV2B). Expression of exogenous Fbxl17 promoted Sufu poly-
ubiquitylation, whereas an Fbxl17 mutant lacking the F-box failed
to do so, indicating that the formation of the SCF is not a pre-
requisite for the binding of Fbxl17 to its substrates, but required for
ubiquitylation (Fig 2D).
Furthermore, we observed that Fbxl17 used the lysine 257 of
Sufu as a preferential attachment site for ubiquitin, since the poly-
ubiquitylation of Sufu mutant K257R was impaired (Fig 2E). Using
reticulocyte lysates, we reconstituted the components of the
SCFFbxl17 and Sufu in an in vitro reaction, as previously done
(Peschiaroli et al, 2006). We observed ubiquitylation of Sufu wild
type (WT), while the Sufu K257R was ubiquitylated to a reduced
extent (Fig EV2C). These findings explain the increased half-life of
Sufu K257R mutant reported elsewhere (Yue et al, 2009) and
suggest that F-box proteins might have preferential ubiquitin attach-
ment sites on substrates.
Fbxl17–Sufu interaction is impaired by Sufu phosphorylation and
favored by the presence of Gli
To gain insights into the details of Fbxl17 recognition of Sufu, we
used Sufu-truncated mutants and measured binding to Fbxl17. A
region of Sufu encompassing amino acids 350–425 was found to be
sufficient for the binding to Fbxl17 (Fig EV3A–C). Phosphorylation is
a common mechanism used by F-box proteins for substrate recogni-
tion; however, in the case of Fbxls, phosphorylation could also block
substrate recognition (Kuchay et al, 2013; Skaar et al, 2013).
Sufu WT was unable to bind Fbxl17 efficiently as the Sufu 350–
484-truncated mutant (Fig EV3B), suggesting the presence of a
phosphorylation event on Sufu, that might prevent Fbxl17 binding
outside of the minimal binding region. Thus, we systematically
mutagenized all the serine and threonine residues to alanine on
Sufu between the residues 1 and 350. While the majority of sites did
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Figure 2. SCFFbxl17 mediates Sufu polyubiquitylation.
A Detection of polyubiquitylated species of endogenous Sufu co-
immunopurified from DAOY cells transfected with Myc-tagged ubiquitin
(Ub) either in the presence of nontargeting siRNA (Control) or in the
presence of two siRNAs against Fbxl17 (1) and (2). MG132 (10 lM) was
added in all samples.
B Detection of polyubiquitylated species of Sufu upon co-transfection of
HEK293T cells with HA-tagged Sufu and Myc-tagged ubiquitin (Ub) either
in the presence of nontargeting siRNA (Control) or in the presence of two
siRNAs against Fbxl17 (1) and (2). MG132 (10 lM) was added in all samples.
C Fbxl17 mRNA relative levels in DAOY and HEK293T cells upon Fbxl17
depletion with either a nontargeting siRNA (Control) or two siRNAs to
Fbxl17 (1) and (2). Data are shown as mean  SEM.
D Detection of ubiquitylated Sufu co-immunoprecipitated from HEK293T cells
co-transfected with HA-tagged Sufu, Myc-ubiquitin (Ub) along with either
Flag-tagged Fbxl17 wild type (WT) or a mutant lacking the F-box domain
(Fbxl17DF). MG132 (10 lM) was added in all samples.
E Detection of ubiquitylated Sufu co-immunoprecipitated from HEK293T cells
co-transfected with Myc-tagged ubiquitin (Ub), Flag-tagged Fbxl17, and
HA-tagged Sufu WT or Sufu mutant K257R. MG132 (10 lM) was added in
all samples.
The EMBO Journal ª 2016 The Authors
The EMBO Journal Fbxl17 mediates Sufu polyubiquitylation Madalina Raducu et al
4
Published online: May 27, 2016 
not affect the binding of Fbxl17 to Sufu (Fig EV3E and F), a mutant
of Sufu in which the S342 and S346 residues were changed to
alanine (A) increased binding to Fbxl17 (Fig 3A). Substitution of
S342 and S346 to D (S342/6D) to mimic phosphorylation decreased
recognition by Fbxl17 (Fig 3A). These data are consistent with the
increased stabilization of Sufu detected upon the phosphorylation of
these residues by PKA (protein kinase A) and GSK3b (glycogen
synthase kinase 3b) (Chen et al, 2011).
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Figure 3. Fbxl17–Sufu interaction is impaired by Sufu phosphorylation and favored by the presence of Gli.
A Detection of Myc-tagged Fbxl17 after immunoprecipitation of HA-tagged Sufu WT or Sufu S342/6A and S342/6D, as indicated. HEK293T cells were treated with
MLN4924 (2 lM) for 5 h prior to collection.
B Detection of Flag-tagged Gli1 and Myc-tagged Fbxl17 binding to immunoprecipitated HA-tagged Sufu wild type (WT) or to Sufu S352F. An empty vector (EV) was used
as a negative control. HEK293T cells were treated with MLN4924 (2 lM) for 5 h prior to collection.
C Detection of Sufu phosphorylated on S352/T353 after immunoprecipitation of HA-tagged Sufu WT and Sufu 351–353 AAA, as indicated.
D Detection of Myc-tagged Fbxl17 binding to Sufu full-length (FL) or to the following Sufu peptides: Sufu 340–360 (APSRKDSLESDSSTAIIPHEL); Sufu 340–360 [S352P/
T353P] (phosphorylated on the residues S352 and T353); Sufu 351–372 (SSTAIIPHELIRTRQLESVHLK).
E Detection of HA-tagged Sufu binding to a Myc-tagged Fbxl17 construct encompassing the residues 318–701 (corresponding to the F-box motif and C-terminus
region) assessed by in vitro binding assay. Both proteins were synthesized in vitro using a T7-coupled reticulocyte lysate system.
F Detection of ubiquitylated Sufu immunoprecipitated from HEK293T cells co-transfected with HA-tagged ubiquitin (Ub), Myc-tagged Fbxl17, and Flag-tagged Gli1.
MG132 (10 lM) was added in all samples.
G Detection of Flag-tagged Gli1 binding to Myc-tagged Fbxl17 co-immunoprecipitated from HEK293T cells transfected with a nontargeting siRNA (Control) or two siRNA
to Sufu (1) and (2), as indicated.
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Within the minimal binding region of Sufu to Fbxl17, Sufu has
been found phosphorylated on S352 (Hsu et al, 2011). A natural
occurring mutation (S352F) abolishing S352 phosphorylation has
been described in the medulloblastoma of patients affected by
Gorlin syndrome (Smith et al, 2014). Therefore, we tested Fbxl17
binding to Sufu S352F. The Sufu S352F substitution increased
Fbxl17 binding (Fig 3B); on the contrary, a mutant of Sufu where
the S352 residue was changed to aspartate (D) to mimic the phos-
phorylation showed reduced binding to Fbxl17 (Fig EV3D). We
performed LC/MS analysis to obtain high coverage of Sufu modifi-
cations and identified multiple phosphorylation sites in this region
(Appendix Fig S1A). Furthermore, we generated a phospho-specific
antibody against a peptide of Sufu containing both S352 and T353
residues phosphorylated. The antibody recognizes Sufu WT, indicat-
ing that S352 and T353 are phosphorylated in vivo, but did not
recognize a mutant of Sufu where S352 and T353 were substituted
to alanine (S351-T353AAA) (Fig 3C).
Given the crucial role of residues S342, S346, and S352 for
Fbxl17–Sufu interaction, we tested whether Fbxl17 is able to bind to
a linear peptide encompassing amino acids 340–360 (with and with-
out the phosphorylation of S352/T353 residues) and 351–372. Inde-
pendently of the phosphorylation status of S352 residue, Fbxl17
purified from the cells did not bind to Sufu peptides, but interacted
with full-length Sufu in vitro, indicating that a linear sequence is not
sufficient for Fbxl17 binding (Fig 3D). Additionally, Fbxl17 and Sufu
synthesized in vitro were able to bind, pinpointing that the interac-
tion is direct and independent of post-translational modifications
induced by Hh signaling (Fig 3E).
Fbxws utilize the WD40 domain to interact with phosphorylated
linear degradation sequences; however in the case of the Fbxls, the
leucine zipper motif is contacting a larger surface and could require
the presence of cofactors (Hao et al, 2005; Xing et al, 2013). The
conformation of Sufu is regulated by Gli binding and Sufu–Gli inter-
action requires an intact tertiary structure of Sufu (Cherry et al,
2013; Zhang et al, 2013). Thus, we asked whether Gli1 acts as a
cofactor modulating the interaction between Fbxl17 and Sufu
in vivo. Remarkably, Fbxl17 polyubiquitylation of endogenous Sufu
was favored by the presence of exogenous Gli1 that promoted an
increased binding of Fbxl17 to Sufu and the subsequent polyubiqui-
tylation (Fig 3F). To assess that the latter was due to the direct inter-
action between Fbxl17 and Sufu, we depleted Sufu using two
different siRNA and tested the binding of Gli1 to Fbxl17. Sufu
depletion abolished the binding of Gli1 to Fbxl17, indicating that
Sufu bridges the interaction between Fbxl17 and Gli1 in vivo
(Fig 3G).
Sufu ubiquitylation by Fbxl17 allows Gli dissociation for
Hedgehog signaling activation
It is not well understood how Sufu is released from Gli1 for full Hh
pathway activation. We speculated that Fbxl17 could mediate the
release by promoting Sufu polyubiquitylation and degradation. To
assess the latter, we analyzed Sufu protein levels in mouse embry-
onic fibroblasts (MEFs) that express the receptor Ptch1 (Ptch1+/+),
MEFs with heterozygous loss of Ptch1 (Ptch1+/), and MEFs defi-
cient in Ptch1 (Ptch1/), which have constitutive Hh signaling
(Taipale et al, 2000). Strikingly, MEFs Ptch1/ and Ptch1+/ cells
showed a decrease in Sufu levels corresponding to the degree of Ptch
loss and the consequent Hh activation. Sufu levels were reduced in
Ptch1/ and less significantly in Ptch1+/, while remained unaf-
fected in Ptch1+/+, indicating that Fbxl17 is acting downstream of
Ptch and Smo. Low levels of Sufu present in MEFs Ptch1+/ and
MEFs Ptch1/ were restored to levels comparable to Ptch1+/+ by
Fbxl17 depletion (Fig 4A and B). Furthermore, MEFs Ptch1/ lack-
ing Fbxl17 presented low transcription levels of Hh target genes such
as Gli1 and Bcl2 due to a negative effect that Sufu accumulation
exerts on Gli-mediated target gene expression (Fig 4C and D).
Considering the defects observed in pathway activation upon
Fbxl17 depletion in MEFs Ptch1/ cells and that Fbxl17 preferen-
tially binds to the Sufu–Gli complex, we speculated that Fbxl17
polyubiquitylation favors Sufu–Gli complex dissociation to allow
the need to be substituted with Hh pathway activation. Indeed,
Fbxl17 overexpression induced Sufu degradation and Gli1 release,
whereas the depletion of Fbxl17 in MEFs Ptch1/ led to an accumu-
lation of Sufu–Gli1 complexes (Fig 4E and Appendix Fig S1B). Since
the polyubiquitylation of Sufu precedes degradation, this model is in
accordance with previous findings on Sufu–Gli complex formation
and dissociation (Tukachinsky et al, 2010).
Finally, we addressed where the degradation of Sufu takes place
in cells MEFs Ptch1/ where the pathway is constitutively acti-
vated. Due to the lack of an antibody detecting endogenous Fbxl17
by immunofluorescence, we stably expressed Fbxl17 using a retrovi-
ral system that maintains physiological levels of protein expression.
To avoid localization artifacts, we expressed an Fbxl17 tagged with
▸Figure 4. Sufu ubiquitylation by Fbxl17 allows Gli dissociation for Hedgehog signaling activation.A Sufu protein levels in mouse embryonic fibroblasts (MEFs) Ptch1+/+, Ptch1+/, and Ptch1/ transfected with a nontargeting siRNA (Control) or two siRNAs targeting
mouse Fbxl17 (1) and (2).
B Quantification of Fbxl17 mRNA levels in MEFs Ptch1+/+, Ptch1+/, and Ptch1/ transfected as in (A). Data are shown as mean  SEM.
C Analysis of Gli1 mRNA levels in MEFs Ptch1+/+ and Ptch1/ upon Fbxl17 depletion using two different siRNAs (mean  SEM from three independent experiments,
***P < 0.0005, unpaired t-test).
D Analysis of Bcl2 mRNA levels in MEFs Ptch1+/+ and Ptch1/ upon Fbxl17 depletion using two different siRNAs (mean  SEM from three independent experiments,
**P < 0.005, ***P < 0.0005, unpaired t-test).
E Detection of Flag-tagged Gli1 binding to HA-tagged Sufu in MEFs Ptch1/ upon expression of Myc-tagged Fbxl17, or Fbxl17 depletion by two siRNAs. For each
condition, 200 lg of whole-cell lysate was immunoprecipitated.
F Immunostaining of Fbxl17 using anti-Myc antibody in Ptch1/ MEFs stably transduced with a pBABE vector expressing Fbxl17 tagged with Myc either at the
N-terminus [Myc(N)-Fbxl17] or at the C-terminus [Myc(C)-Fbxl17]. Scale bars: 20 lm.
G Detection of Fbxl17 using anti-Myc antibody in Ptch1/ MEFs stably expressing Myc(N)-Fbxl17 (Fbxl17 tagged at the N-terminus) and Myc(C)-Fbxl17 (Fbxl17 tagged
at the C-terminus).
H Detection of HA-tagged Fbxl17 binding to endogenous Sufu immunoprecipitated from cytoplasmic and nuclear extracts from Ptch1/ MEFs. Asterisk (*) indicates a
nonspecific band. Identification of cytoplasmic and nuclear fractions was performed by lamin A/C and GAPDH detection.
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Myc at the C-terminus and N-terminus. In both cases, the localiza-
tion of Fbxl17 in MEFs Ptch1/ was exclusively nuclear (Fig 4F
and G). Furthermore, exogenous Fbxl17 expressed in MEFs
Ptch1/ induced downregulation of Sufu in the nucleus, where
Fbxl17 interacted with Sufu upon biochemical fractionation of the
cytoplasmic and nuclear extracts (Fig 4H). Since phosphorylation of
Sufu on S342/S346 promotes ciliary retention of Sufu (Chen et al,
2011), these data are in accordance with a model where Sufu
dephosphorylation promotes the localization outside the cilium and
ubiquitin mediated proteolysis by Fbxl17.
Fbxl17-mediated degradation of Sufu regulates Hh signaling,
cancer cell proliferation, and medulloblastoma growth
Given the relevant role of Fbxl17 in regulating Hh signaling and that
Hh signaling activity has been implicated in the proliferation of
prostate cancer cell lines (Karhadkar et al, 2004; Sanchez et al,
2004), we further tested the effect of Fbxl17 on Hh activation by
quantifying Gli1 mRNA levels upon either depletion or expression of
Fbxl17 using PC3 cells. Fbxl17 silencing resulted in a decrease in
Gli1 mRNA levels (Appendix Fig S2A), and contrarily, Fbxl17 expres-
sion led to an increase in Gli1 mRNA levels (Appendix Fig S2B).
Since proliferation of PC3 cells is in part dependent on Hh signaling
pathway (Karhadkar et al, 2004; Zhang et al, 2007), we evaluated
whether Fbxl17 depletion impairs the prostate cancer cell prolifera-
tion. Fbxl17 silencing induced a defective cell proliferation of PC3
cells and this defect was rescued by the reintroduction of Fbxl17 full
length in cells depleted of Fbxl17 (Appendix Fig S2C–F). Moreover,
this phenotype was dependent on the accumulation of Sufu, as
double siRNA of Fbxl17 and Sufu could restore the proliferation
(Appendix Fig S3A–D).
A more direct role of Hh pathway has been established in the
pathogenesis of medulloblastoma characterized by the presence of
mutations in central components of Hh signaling (Kool et al, 2014);
therefore, we tested whether the Fbxl17–Sufu axis operates in medul-
loblastoma cancer cells. DAOY human medulloblastoma cells have
been reported to be responsive to Hh signaling modulation (Gotschel
et al, 2013). DAOY cells responded to Smo activation (using SAG;
Smo agonist) or inhibition (using cyclopamine; Smo antagonist) by
upregulating or downregulating Gli1 mRNA levels, respectively
(Fig EV4A). Silencing of Fbxl17 impaired Gli1 transcription upon
SAG-induced Hh activation (Fig EV4B–D). Additionally, upon the
stimulation of DAOY cells with SHH (Sonic Hedgehog)-conditioned
media (Fig EV4E), Sufu protein levels were reduced (Fig EV4F).
Fbxl17 depletion restored Sufu protein levels after SHH-conditioned
media (Fig EV4F and quantified in EV4G), confirming that the
downstream activation of Hh signaling pathway depends on
Fbxl17-mediated degradation of Sufu in DAOY cells. The observed
downregulation of Sufu protein was not due to the variation in
Fbxl17 expression upon Hh stimulation. Indeed, the mRNA of Fbxl17
was not affected in DAOY cells upon Hh stimulation with SAG or
SHH ligand and Hh inhibition with cyclopamine (Fig EV4H and I).
Similar to PC3 cells, we evaluated whether Fbxl17 depletion
impairs DAOY cell proliferation. Proliferation of DAOY cells was
hampered by Fbxl17 depletion and stimulated by Fbxl17 re-expression
(Fig 5A). Fbxl17 siRNA (quantified in Fig 5B) increased protein
levels of Sufu; on the contrary, expression of Fbxl17 corresponded
to low protein levels of Sufu in DAOY (Fig 5C and Appendix Fig
S4A). Importantly, the proliferation defect induced by Fbxl17 deple-
tion was dependent on the accumulation of Sufu, as double siRNA
of Fbxl17 and Sufu could restore proliferation in DAOY (Fig 5D–F
and Appendix Fig S4B).
To investigate the relevance of Fbxl17–Sufu axis in cancer, we
assessed the effect of RNAi of Fbxl17 in vivo by using an orthotopic
rat model of medulloblastoma. Fbxl17 RNAi led to an impaired Hh
signaling reflected by the accumulation of Sufu protein and
decreased Gli1 mRNA (Fig 6A–C and Appendix Fig S5A).
In vivo T2-weighted magnetic resonance imaging (MRI) showed a
marked reduction in tumor progression over time with RNAi against
Fbxl17 (Fig 6D and E). In contrast, the area of gadolinium enhance-
ment on T1-weighted images at the end-point showed no differences
between groups (Appendix Fig S5B and C). Histologically, tumors
with RNAi against Fbxl17 showed significantly reduced growth
compared to a nontargeting control as detected by vimentin staining
(6.1  1.7 mm2 vs. 12.4  1.3 mm2; P < 0.05; Fig 6F and G), and
also a significantly lower proliferative index within the tumor tissue
(5.4  3.6% vs. 20.8  2.8%; P < 0.05; Fig 5H and I). Together,
these data suggest that T2-weighted MRI may be more sensitive to
inhibition of tumor growth than post-contrast T1-weighted MRI in
this setting.
Fbxl17–Sufu axis is altered in medulloblastoma
According to the gene transcription profiles, four different subtypes
of medulloblastoma have been described, that is, wingless type
(Wnt), Sonic Hedgehog (SHH), group 3, and group 4 (Gajjar &
Robinson, 2014). The SHH subtype of medulloblastoma is character-
ized by an increased Hh signaling due to the altered expression of
pathway components. Given the relevant role of Fbxl17 in Hh
signaling and medulloblastoma growth, we analyzed the mRNA
expression of Fbxl17 and Sufu reported in the largest published
medulloblastoma expression profiling study (N = 285 primary
samples) (Northcott et al, 2012). Although Sufu has a pivotal role in
Hh signaling and mutations in Sufu are present in SHH medulloblas-
toma, the mRNA of Sufu was found to be not reduced in the SHH
subtype, whereas Gli1 was found to be drastically increased (Fig 7A
and B). Strikingly, Fbxl17 mRNA was found to be significantly
increased in the SHH-subtype medulloblastoma (Fig 7C) and the
levels of Fbxl17 and Gli1 positively correlated (Spearman’s
rho = 0.5640; P < 0.00001; Fig 7D). In the absence of Sufu mRNA
alterations, these results suggest that in medulloblastoma the
control of Sufu protein levels by Fbxl17 plays a prominent role in
sustaining Hh activation.
The distinction of four molecular subgroups depends on the tran-
scriptional profiles of the subgroups, which at least for SHH subtype
reflects the cells of origin of the medulloblastoma. In the SHH
subtype is established that granule cell progenitors (GCPs) represent
the cell of origin of the malignancy (Wechsler-Reya & Scott, 1999;
Marino et al, 2000; Oliver et al, 2005; Schuller et al, 2008). Thus,
we tested the effect of siRNA and the expression of Fbxl17 in GCPs.
Similar to the results obtained in DAOY, Fbxl17 expression
increased cell proliferation (Fig EV5A and B); on the contrary,
siRNA of Fbxl17 reduced cell proliferation measured by BrdU incor-
poration (Fig EV5C and D).
To establish a role for Fbxl17 in the etiology of medulloblastoma
through Sufu mutation, we investigated in more detail the Sufu
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S352F substitution, which favors binding to Fbxl17 (Fig 3A). This
substitution appears in the medulloblastoma of patients affected by
Gorlin syndrome and contributes to the medulloblastoma develop-
ment, in the absence of other alterations in Hh pathway (Smith
et al, 2014). We observed that the half-life of Sufu S352F was found
to be decreased compared to Sufu WT, in accordance with an
increased binding to Fbxl17. Furthermore, silencing of Fbxl17
restored Sufu mutant half-life (Fig 7E). Using firefly luciferase-based
Gli-reporter assay (Sasaki et al, 1997), we assessed the effect of Sufu
S352F on Hh activation in MEFs Sufu/ reconstituted with either
Sufu WT or SufuS352F. Strikingly, Sufu S352F increased the respon-
siveness of cells to Hh agonist (SAG) (Fig 7F), indicating that the
faster proteolysis of Sufu, mediated by Fbxl17, has a functional role
in the control of Hh signaling.
These observations exemplify the role of Fbxl17–Sufu axis alter-
ations in medulloblastoma.
Discussion
Our findings identify Fbxl17 as a novel regulator of Hh signaling
pathway. Fbxl17 mediates Sufu polyubiquitylation and degradation
through the proteasome. The interaction between Fbxl17 and Sufu
is hampered by the phosphorylation of Sufu on S342 and S346 resi-
dues, which were shown to be target sites for PKA and GSK3b,
respectively (Chen et al, 2011) (Fig 8A). Phosphorylation of Sufu
retains it in the primary cilium (Chen et al, 2011) and could repre-
sent a failsafe mechanism to avoid unscheduled pathway activation
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Figure 5. Fbxl17-mediated degradation of Sufu promotes medulloblastoma cell proliferation.
A Cell proliferation of DAOY cells upon Fbxl17 depletion using a nontargeting siRNA (Control), two siRNAs against Fbxl17 (1) and (2) or upon reintroduction of a Myc-
tagged Fbxl17 construct in Fbxl17-depleted DAOY cells using siRNA Fbxl17 (2) (mean  SEM from three independent experiments, **P < 0.005; ***P < 0.0005,
unpaired t-test).
B Quantification of Fbxl17 mRNA levels in DAOY cells transfected with a nontargeting siRNA (Control) or two siRNAs against Fbxl17 (1) and (2) (mean  SEM from
three independent experiments, **P < 0.005, unpaired t-test).
C Sufu protein levels in DAOY cells treated as in (A). Representative image of three independent experiments is shown.
D Cell proliferation of DAOY cells transfected with nontargeting siRNA (Control), siRNA against Fbxl17 or a combination of siRNA targeting Fbxl17 and Sufu
(mean  SEM from three independent experiments, **P < 0.005; ***P < 0.0005, unpaired t-test).
E Quantification of Fbxl17 mRNA levels in DAOY cells treated as in (D) (mean  SEM from three independent experiments, ***P < 0.0005, unpaired t-test).
F Sufu protein levels in DAOY cells treated as in (D). Representative image of three independent experiments is shown.
Source data are available online for this figure.
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Figure 6. Fbxl17-mediated degradation of Sufu promotes medulloblastoma tumor growth.
A Quantification of Fbxl17 mRNA levels in DAOY cells transfected with control shRNA or shRNA targeting Fbxl17 (mean  SEM from three independent experiments,
***P < 0.0005, unpaired t-test).
B Detection of Sufu protein levels in DAOY cells transfected with control shRNA or shRNA Fbxl17. Representative image of three independent experiments is shown.
C Quantification of Gli1 mRNA levels in DAOY cells transfected with control shRNA or shRNA Fbxl17 (mean  SEM from three independent experiments, **P < 0.005,
unpaired t-test).
D T2-weighted magnetic resonance images showing tumor development in rats injected with DAOY cells transfected with control shRNA or shRNA against Fbxl17. One
representative image for each condition at 10 weeks is shown. Scale bar: 5 mm.
E Graph showing area of T2 hyperintensity (a surrogate marker of tumor growth) between 4 and 10 weeks post-tumor induction. Animals were injected with DAOY cells
stably expressing control shRNA or shRNA against Fbxl17 (10,000 cells/ll) (mean  SEM; n = 5; two-way ANOVA, followed by unpaired t-test, *P < 0.05, **P < 0.01).
F Representative immunohistochemical image of vimentin staining. Scale bar: 1 mm.
G Quantification of tumor growth (vimentin staining) in rats injected with DAOY cells transfected with either control shRNA or shRNA against Fbxl17 (mean  SEM;
n = 5; unpaired t-test, *P < 0.05).
H Representative immunohistochemical image of Ki67 staining. Scale bar: 0.5 mm/0.1 mm.
I Quantification of proliferative index (Ki67 staining) in rats injected with DAOY cells transfected with either control shRNA or shRNA against Fbxl17 (mean  SEM;
n = 5; unpaired t-test, *P < 0.05).
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when the Hh ligands are not present. A similar but opposite mecha-
nism of regulation is operated downstream of Sufu at the levels of
Gli2 and Gli3 by the SCF bTrcp ubiquitin ligase. In this case, the
concerted action of PKA and GSK3b generates a phosphorylation-
dependent signal for ubiquitylation by bTrcp (Bhatia et al, 2006;
Wang & Li, 2006). The ubiquitylation of Gli2 and Gli3 generates
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Figure 7. Fbxl17–Sufu axis is altered in medulloblastoma.
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transcriptional repressors to avoid pathway activation. Thus, PKA
and GSK3b act on multiple components of Hh pathway as general
negative regulators (Chen & Jiang, 2013).
Upon Hh ligand binding to Ptch1, a swift activation of the path-
way entails the reversal of PKA and GSK3b phosphorylation on
Sufu S342 and S346, in addition to S352/T353. The dephosphoryla-
tion of Sufu initiates Fbxl17 polyubiquitination of Sufu on lysine
257 for proper signal transduction (Fig 8B). Sufu is upstream of
Gli processing (Humke et al, 2010), and thus, it is tantalizing to
speculate that the dephosphorylation of Sufu promotes Gli dephos-
phorylation for the formation of transcriptional activators. In
medulloblastoma, increased expression of Fbxl17 and substitution
in critical Sufu residues (S352F), required for Fbxl17 binding,
allow amplified pathway activation and increased cell proliferation
(Fig 8C). Inhibition of Fbxl17 blocks Sufu degradation, Hh path-
way activation and prevents medulloblastoma tumor growth
(Fig 8D).
An important feature of Fbxl17–Sufu axis is that Fbxl17 acts
preferentially on Sufu in complex with Gli1, thus selecting for
degradation an active pool of Sufu. Upon Hh signaling activation,
Fbxl17-mediated polyubiquitylation of Sufu induces Sufu–Gli
complex dissociation for the transduction of the Hh signal.
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Figure 8. SCF (Fbxl17) ubiquitylation of Sufu regulates Hedgehog signaling and medulloblastoma growth.
A–D Scheme outlining the mechanism of Sufu recognition by Fbxl17 and its alteration in medulloblastoma.
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Sufu protein levels are exquisitely sensitive to the degree of Hh
activation, indicating that the regulation of Sufu levels by Fbxl17
adds a further layer of control for the generation of more refined
transcriptional programs in physiological conditions. Indeed, Fbxl17
could regulate Sufu levels to fine-tune transcriptional outputs;
however, more studies are required to establish how the upstream
components of the pathway regulate Sufu and Fbxl17. At the same
time, it is noteworthy that Fbxl17 transcription is blocked by methy-
lation in embryonic stem cells and transcribed in neural stem cells
where Hh plays a more active role (Cortese et al, 2011). In line with
this, Fbxl17 expression is increased in the brain and spinal cord
during development (Diez-Roux et al, 2011), pointing out to a role
for Fbxl17 in physiological development. Furthermore, a putative
homolog of Fbxl17 (CG31633) has been described in
D. melanogaster, where the absence of the latter induces a pupal
lethal phenotype (Dui et al, 2012), suggesting an essential role of
Fbxl17 in development.
Mutations in the components of Hh signaling are a feature of
SHH medulloblastoma (Kool et al, 2014). We show that in a case of
familial medulloblastoma, altered proteolysis of Sufu plays an active
role in the induction of sustained Hh signaling. Importantly, muta-
tions in other components of Hh signaling pathway, such as Ptch
(present in > 50% of SHH medulloblastoma) (Kool et al, 2014), will
also affect Sufu protein levels, given the effect of pathway activation
on Sufu protein mediated by Fbxl17. Thus, in the majority of SHH
medulloblastoma, Sufu protein levels will be low due to the consti-
tutive activation of Hh signaling. In these cancers, increasing Sufu
levels through Fbxl17 inhibition could block Hh signaling and cell
proliferation. Overexpression of Fbxl17 in SHH subgroups provides
a therapeutic window to selectively target cancer cells. Thus, our
study highlights Fbxl17 as a novel target for the treatment of SHH
medulloblastoma.
Other mutations of Sufu residing in critical residues for Fbxl17
binding have been described in colorectal cancer and malignant
melanoma (Krauthammer et al, 2012; Giannakis et al, 2014); thus,
alteration in Fbxl17–Sufu axis could be present in other cancer
types. The biological significance of these alterations for cell prolif-
eration remains to be determined in these cancers. The use of Smo
inhibitors for the treatment of medulloblastoma is being tested in
the clinic with encouraging results (Robinson et al, 2015), but could
be significantly prevented by the acquisition of resistance through
secondary Smo mutations, described in basal cell carcinoma and
medulloblastoma (Yauch et al, 2009; Atwood et al, 2015; Sharpe
et al, 2015). In medulloblastoma, the combination of Smo inhibitors
and Fbxl17 inhibitors could be a viable alternative strategy to obtain
sustained responses.
Our findings pave the way for the investigation of therapies
targeting the ubiquitin proteasome system in the treatment for
medulloblastoma and other cancers relying on Hh signaling.
Materials and Methods
Cell culture
All cell lines were routinely cultured in a humidified incubator at
37°C under 5% CO2 in the indicated culture medium containing
10% fetal bovine serum (FBS, Sigma Aldrich) supplemented with
100 U/ml penicillin sodium and 100 lg/ml streptomycin sulfate
(Sigma Aldrich).
HEK293T, HeLa (ATCC, American Type Culture Collection), and
DAOY cells (kind gift from Dr. Maike Glitsch, Department of Physiol-
ogy, Anatomy and Genetics, University of Oxford, UK) were grown
in Dulbecco’s modified Eagle’s medium (DMEM, Gibco/Invitrogen),
while PC3 cells (kindly provided by Dr. Richard Bryant from Ludwig
Institute for Cancer Research, University of Oxford, UK) were main-
tained in RPMI 1640 (Lonza). Ptch1+/+, Ptch1+/, and Ptch1/
mouse embryonic fibroblasts (MEFs, kind gift from Dr. Philip
Beachy, Department of Biochemistry, Stanford University), Sufu/
MEFs (kindly provided by Dr. Stephan Teglund, Department of
Biosciences and Nutrition, Karolinska Institutet, Sweden), and
NIH3T3 cells (ATCC) were cultured in DMEM supplemented with
1 mM sodium pyruvate (Sigma Aldrich) and 0.1 mM MEM
nonessential amino acids (Sigma Aldrich).
Hh pathway assays and production of SHH-conditioned medium
Hyperconfluent DAOY, PC3 cells, and Sufu/ MEFs were starved
for 24 h in serum-reduced medium (DMEM with 0.5% FBS), and
subsequently, the Hh signaling pathway was stimulated using
Smoothened agonist SAG (100 nM, Calbiochem) or Sonic Hedgehog
(SHH)-conditioned medium (1:4). For Hh signaling inhibition, cyclo-
pamine (Sigma Aldrich) was added to the starvation medium at a
final concentration of 10 lM. DMSO (dimethyl sulfoxide) was used
as a solvent and as control vehicle. Ptch1+/+, Ptch1+/, and
Ptch1/ MEFs were assessed after 24 h of maintenance in serum-
starved in serum-reduced medium. SHH-conditioned medium was
generated as described previously (Cherry et al, 2013). After 24 h of
incubation with the appropriate Hh pathway agonists, antagonist, or
control vehicle, cell cultures were harvested for real-time PCR or
Western blotting.
Antibodies
The following monoclonal antibodies were used: anti-Myc (9B11,
mouse, Cell Signaling Technology), anti-HA (05-904, mouse, Milli-
pore and 16B12, Biolegend), anti-Sufu (C81H7, rabbit, Cell Signaling
Technology), anti-lamin A/C (4C11, Cell Signaling Technology), and
anti-vimentin (V9, mouse, Vector Laboratories). Polyclonal antibod-
ies were used as follows: anti-Flag (F7425, rabbit, Sigma Aldrich),
anti-Fbxl17 (PA5-31396, rabbit, Thermo Fisher Scientific Pierce),
anti-GAPDH (MA5-15738, rabbit, Sigma Aldrich), anti-Sufu (C-15,
goat, Santa Cruz Biotechnology), anti-Ki67 (SP6, rabbit, Vector
Laboratories), and anti-Skp1 (kind gift from Dr. Michele Pagano at
NYU Cancer Institute, New York University School of Medicine,
USA). A rabbit polyclonal antibody against the following peptide of
Sufu was raised Hu #347~360: CLESDS-pS-pT-AIIPHEL. To ensure
the specific recognition of phosphorylated Sufu, the antibody was
affinity-purified against a phosphorylated peptide and absorbed
against a nonphosphorylated peptide CLESDSSTAIIPHEL.
Liquid chromatography–tandem mass spectrometry
(LC-MS/MS) analysis
Flag/Myc-tagged Fbxl17 co-immunopurified material was eluted by
competition using Flag peptide. Supernatant material was subjected
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to two rounds of chloroform–methanol precipitation as described
(Wessel & Flugge, 1984). Samples were then resuspended in 6 M
urea, 100 mM ammonium acetate pH ~8 and subjected to in-solution
trypsin digestion and analysis by nano-liquid chromatography–
tandem mass spectrometry as described previously (Ternette et al,
2013). In brief, after solubilization of the sample pellets, 3 ll of
trypsin (20 ng/ll, Promega) was added to the samples diluted six
times with H2O for an overnight digestion at 37°C. The samples were
then desalted using a C18 SEP PAK cartridge according to the manu-
facturer’s instructions (Waters), dried via Speed Vac centrifugation,
and resuspended in 20 ll of a 2% CH3CN/0.1% TFA solution.
Peptides were analyzed by nano-liquid chromatography–tandem
mass spectrometry (nano-LC-MS/MS) using a Nano-Acquity-UPLC
(C18 column with a 75 lm × 250 mm, 1.7 lm particle size; Waters)
coupled to an Orbitrap Velos tandem mass spectrometer (Thermo
Scientific, Bremen, Germany) with a resolution of 70,000 full-width
half maximum at mass/charge 400, top 15 precursor ion selection,
and fragmentation performed in collision-induced dissociation (CID)
mode. The samples were loaded in 99.5% buffer A (0.1% FA in
H2O). The gradient used to elute the peptides started by a 3-min
isocratic gradient composed of 3% buffer B (0.1% FA in CH3CN)
followed by a linear gradient from 3–40% of buffer B for 60 min at a
flow rate of 250 nl/min and a two washes with 97% of buffer B for
3 min. The total length of the analysis was 100 min to allow the
column re-equilibration. The raw MS data were converted into
Mascot generic files using MSconvert (Kessner et al, 2008). Searches
were performed using Matrix Science software using the following
parameters: The error tolerance was fixed at 20 ppm for precursor
ions and at 0.5 Da for fragment ions. The enzyme used was trypsin
and only one missed cleavage was allowed. MS data were searched
against the human uniprot-swissprot database (UniProt_SwissProt,
human 20,353 sequences) in which the false discovery rate (FDR)
was estimated using a decoy database approach (Mascot) and set
to 1%.
In vivo and in vitro ubiquitylation assay
HEK293T cells were plated in 10-cm culture dishes at 80% conflu-
ence, and 24 h later, the cells were transfected with the indicated
plasmids and incubated for 48 h. The cells were treated with
MG132 (10 lM) for 5 h prior to collection. For Fbxl17 silencing,
two rounds of siRNA transfections were performed, and the plas-
mids were delivered to the cells along with the siRNA duplexes in
the first round of transfection. Twenty-four hours after the second
round of transfection, the cells were treated with MG132 and
collected 5 h later. The cells were lysed in LB and ubiquitylated
Sufu was co-immunoprecipitated using either anti-HA or anti-Sufu
antibody coupled to Protein G agarose beads. Polyubiquitinated
forms of Sufu were detected by immunoblot using anti-Myc or anti-
HA as indicated.
In vitro ubiquitylation assay was performed using proteins trans-
lated in a reticulocyte system, as previously done for SCF bTrcp
(Dorrello et al, 2006). Myc-tagged Fbxl17 (318–701) and Sufu WT
or Sufu K257R were in vitro translated using TnT Quick Coupled
Transcription/Translation System reticulocyte system from Promega
according to the manufacturer’s instructions. After translation,
Fbxl17 was mixed with Sufu WT or Sufu K257R in a volume of
40 ll containing 0.1 lM E1 (Boston Biochem), 10 ng/ll Ubch3,
10 ng/ll Ubch5c, 1 lM ubiquitin aldehyde, 2.5 lg/ll ubiquitin
(Sigma), in a ubiquitylation buffer (50 mM Tris pH 7.6, 2 mM ATP,
5 mM MgCl2, 0.6 mM DTT, okadaic acid 0.1 lM). The reaction
mixtures were incubated at 30°C for the indicated times and
analyzed by Western blot of Sufu as indicated.
In vitro binding assay
HA-tagged Sufu full-length and Myc-tagged-Fbxl17 construct 318–
701 was in vitro-transcribed and translated using TNT Quick
Coupled Transcription/Translation System (Promega) according to
the manufacturer’s instructions. Proteins were incubated on ice for
1 h followed by co-immunoprecipitation of Myc-tagged Fbxl17,
using anti-Myc antibody, in binding buffer containing 50 mM Tris–
HCl pH 7.5, 100 mM NaCl, 2 mM EDTA, 0.1% NP-40, and protease
inhibitors. Reactions were stopped with Laemmli buffer and
resolved by SDS–PAGE.
Sufu peptides Sufu (340–360), Sufu (340–360) phosphorylated on
S352 and T353, and Sufu (351–372) (synthesized by ChinaPeptides
Co., Ltd.) were conjugated to CNBr-activated Sepharose (GE Health-
care) according to the supplier’s specifications. HA-tagged Sufu full
length synthesized as described above and bound to Protein G–
Sepharose beads was used as a positive control. Cell lysates of
HEK293T cells transfected with Myc-tagged Fbxl17 were used to
assess the binding to Sufu peptides using standard co-immunopreci-
pitation procedures.
In vivo medulloblastoma model
DAOY cells transfected with either scrambled shRNA or shRNA
against Fbxl17 were cultured until approximately 80–90% confluent
and then resuspended in PBS for intracerebral injection.
Two cohorts (n = 5 per group) of male nude rats (Harlan,
France), 3–4 weeks old, were injected intracerebrally in the cerebel-
lar vermis (11 mm posterior and 0 mm lateral to Bregma, and
depth 1 mm) using a finely drawn glass microcapillary (< 100 lm
tip). Animals were anaesthetized with 2–3% isoflurane in a mixture
of nitrous oxide and oxygen (50%/50%) and placed in a stereotaxic
frame (Stoelting Co.). A midline incision was made in the scalp and
a burr hole drilled. The animals were injected with 104 cells in 1 ll
over a 10-min period. At the end of the injection, the needle was left
in place for 2 min before being slowly removed. Following injection,
the scalp wound was closed and the animals were allowed to
recover from anesthesia.
Magnetic resonance imaging
MRI was performed using a horizontal bore 9.4T magnet with a
Varian DirectDriveTM (Agilent Technologies, Santa Clara, CA, USA).
The animals were anesthetized with 1–2% isoflurane in 70%N2/
30%O2 and a cannula positioned in the tail vein for gadolinium-
DTPA (Gd-DTPA) injection. The animals were positioned in a
quadrature volume transmit coil (i.d. 72 mm) with four phased-
array surface receiver coils (i.d.: 40 mm, RAPID Biomedical GmbH)
and placed in the magnet. Body temperature and respiration were
monitored throughout and maintained at ~37°C and 50 breaths per
min, respectively. Multiparametric MRI was acquired including the
acquisition of T1-weighted images pre- and post-Gd-DTPA injection
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to assess the blood–brain barrier (BBB) integrity, and T2-weighted
images to determine the macroscopic changes in tissue structure, as
previously described (Serres et al, 2014). Briefly, T2-weighted
images were acquired using a fast spin-echo sequence with a repeti-
tion time (TR) of 3.0 s and an effective echo time (TE) of 60 ms.
Spin-echo T1-weighted images (TR = 500 ms; TE = 20 ms) were
acquired both before and 5 min after the injection of 100 ll
Gd-DTPA (Omniscan, GE Healthcare, UK). The matrix size and
field of view were 256 × 256 and 3.5 × 3.5 cm, respectively. In all
cases, a multi-slice acquisition was used, spanning the cerebellum
with axial slice thickness of 1 mm.
Regions of interest (ROI) encompassing areas of visible signal
change in the cerebellar vermis were drawn on both the T2-weighted
and post-Gd-DTPA T1-weighted images, and the areas were calcu-
lated.
Statistical analysis
Quantitative analysis of band intensity was performed using the
Image J program. Data are reported as mean  SEM. Statistical
analyses were performed using GraphPad Prism (GraphPad Soft-
ware, Inc.). Differences between the groups were compared using
unpaired Student’s t-test.
Affymetrix Human Gene 1.1 ST Array profiling of 285 primary
medulloblastoma samples (Northcott et al, 2012) was obtained from
Gene Expression Omnibus database (http://www.ncbi.nlm.nih.
gov/geo), accession: GSE37382. Normalized, logged base 2, gene
expression determined using Affymetrix Expression Console (1.1) as
previously described (Northcott et al, 2012) was considered. One-
way ANOVA and Kruskal–Wallis tests were both used to test the
equality of expression values between the groups. Spearman’s rank
correlation test was used to test the gene expression association.
Data analysis was performed using R.
Expanded View for this article is available online.
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